Assetmark Inc. boosted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 19.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 44,658 shares of the biopharmaceutical company’s stock after purchasing an additional 7,152 shares during the period. Assetmark Inc.’s holdings in Amicus Therapeutics were worth $495,000 as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. Van ECK Associates Corp grew its holdings in Amicus Therapeutics by 48.9% during the 4th quarter. Van ECK Associates Corp now owns 2,988 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 981 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Amicus Therapeutics by 33.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 3,807 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 953 shares in the last quarter. First Horizon Advisors Inc. grew its stake in Amicus Therapeutics by 37.3% in the 4th quarter. First Horizon Advisors Inc. now owns 3,856 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 1,048 shares in the last quarter. Parallel Advisors LLC boosted its stake in shares of Amicus Therapeutics by 72.4% during the fourth quarter. Parallel Advisors LLC now owns 6,099 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 2,562 shares in the last quarter. Finally, Point72 Middle East FZE bought a new position in shares of Amicus Therapeutics during the fourth quarter valued at approximately $81,000.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on shares of Amicus Therapeutics in a research note on Thursday, May 18th. They set a “buy” rating on the stock. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.20.
Insider Activity at Amicus Therapeutics
In other news, CAO Samantha Prout sold 36,909 shares of Amicus Therapeutics stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $14.01, for a total transaction of $517,095.09. Following the completion of the sale, the chief accounting officer now directly owns 137,003 shares in the company, valued at $1,919,412.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CAO Samantha Prout sold 36,909 shares of Amicus Therapeutics stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $14.01, for a total transaction of $517,095.09. Following the completion of the sale, the chief accounting officer now directly owns 137,003 shares in the company, valued at $1,919,412.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Chairman John F. Crowley sold 6,044 shares of Amicus Therapeutics stock in a transaction on Monday, July 17th. The stock was sold at an average price of $13.45, for a total transaction of $81,291.80. Following the sale, the chairman now owns 938,185 shares of the company’s stock, valued at $12,618,588.25. The disclosure for this sale can be found here. Insiders sold 126,373 shares of company stock valued at $1,635,775 over the last 90 days. Insiders own 2.10% of the company’s stock.
Amicus Therapeutics Trading Up 1.1 %
NASDAQ:FOLD opened at $13.42 on Friday. Amicus Therapeutics, Inc. has a 52 week low of $9.10 and a 52 week high of $14.10. The firm has a 50 day moving average of $12.92 and a 200 day moving average of $12.28. The company has a quick ratio of 2.69, a current ratio of 2.72 and a debt-to-equity ratio of 3.53. The stock has a market capitalization of $3.82 billion, a price-to-earnings ratio of -20.97 and a beta of 0.84.
Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) last posted its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Amicus Therapeutics had a negative net margin of 52.85% and a negative return on equity of 157.79%. The firm had revenue of $86.27 million for the quarter, compared to analysts’ expectations of $82.14 million. As a group, sell-side analysts anticipate that Amicus Therapeutics, Inc. will post -0.48 earnings per share for the current fiscal year.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.
Read More
- Five stocks we like better than Amicus Therapeutics
- How to Invest in Hotel Stocks
- Investing in Coffee: 3 Great Strategies to Consider
- How is Compound Interest Calculated?
- 5 Best Stocks to Buy in a Bear Market
- Why Consider Investing in Nanotechnology Stocks
- 3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
